|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | UV treatment of chronic skin graft-versus-host disease--focus on UVA1 and extracorporeal photopheresis显示文摘 | Greinix HT Tanew A | | 0，，： | 1 |
| 2 | UV treatment of chronic skin graft-versus-host disease : focus on UVA1 and extracorporeal photopheresis 显示文摘 | Greinix HT Tanew A | 2012 | Curr Probl Dermatol2012，43，： | 1 |
| 3 | Autoimmune diseases in vitiligo : do anti-nuclear antibodies decrease thyroid volume显示文摘 | Zettinig G Tanew A Fischer G | 2003 | Clin Exp Immunal2003，131，2： | 1 |
| 4 | Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume显示文摘 | Zettinig G Tanew A Fischer G | 2003 | Clin Exp Immunol2003，131，2： | 1 |
| 5 | Guidelines for the management of vitiligo: the European Dermatology Forum consensus显示文摘 | A. Taieb A. Alomar M. B?hm M.L. Dell’Anna A. De Pase V. Eleftheriadou K. Ezzedine Y. Gauthier D.J. Gawkrodger T. Jouary G. Leone S. Moretti L. Nieuweboer‐Krobotova M.J. Olsson D. Parsad T. Passeron A. Tanew W. van der Veen N. van Geel M. Whitton A. Wolker | 2012 | British Journal of Dermatology2012，，1： | 1 |
| 6 | A comparison of psoralen plus ultraviolet A(PUVA) monotherapy,tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis显示文摘 | Tzaneva S Honigsmann H Tanew A | 2002 | Br J Dermatol2002，147，4： | 1 |
| 7 | Autoimmune diseases in vitiligo:do antinuclear antibodies decrease thyroid volume显示文摘 | Zettinig G Tanew A Fischer G | 2003 | Clin Exp Immunol2003，131，2： | 1 |
| 8 | Autoimmune diseases in vitiligo:do anti-nuclear antibodies decrease thyroid volume显示文摘 | Zettinig G Tanew A Fischer G | 2003 | Clin Exp Immunol2003，131，2： | 1 |
| 9 | A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis显示文摘 | Tzaneva S Honigsmann H Tanew A | 2002 | Br J Dermatol2002，147，4： | 1 |
| 10 | A comparison of psoralenplus ultraviolet A (PUVA) monotherapy, tacal- citolplus PUVA and tazarotene plus t'UVA in patients with chronic plaque-type psoriasis显示文摘 | Tzaneva S Honigsmann H Tanew A | 2002 | Br J Dermatol2002，147，4： | 1 |
| 11 | 3种光剂量δ-氨基-γ-酮戊酸光动力疗法治疗光线性角化病的疗效:一项随机、观察者盲法、患者自评的比较研究显示文摘Background: Topical 5- aminolevulinic acid- based photodynamic therapy (ALA- PDT) has been established in recent years as an effective treatment for disseminated actinic keratosis (AK). As yet, however, data are lacking to define the optimal light dose for activation of ALA- induced protoporphyrin IX in AK. Objective: In the present study our purpose was to compare the efficacy and tolerability of 3 different doses of red light for ALA- PDT of AK. Methods: Twenty- seven patients with at least 3 clearly definable, mild or moderate AKs on the scalp or face entered the study. After occlusion for 4 hours with 20% ALA, one AK each was irradiated at random with a single dose of 70, 100, or 140 J/cm2. PDT- induced pain was assessed by the patients by means of a visual analog scale that graded pain intensity between 0 and 10. Follow- up examinations were performed 1 and 3 months after PDT. Results: One month after PDT, the rate of complete remission (CR)was 89% for 70 J/cm2, 92% for 100 J/cm2, and 81% for 140 J/cm2. The CR rates at 3 months were 81% for 70 J/cm2, 77% for 100 J/cm2, and 69% for 140 J/cm2. No significant difference in therapeutic efficacy was found among the 3 light doses at either 1month (P = .36) or 3 months (P=.96) after PDT. The degree of PDT- induced pain during irradiation was substantial and not statistically different (P=.06) for all 3 light doses. Limitations: The conclusions from this study are limited by the small sample size and only apply to topical ALA- PDT. Conclusion: Our results indicate that a red light dose of 70 J/cm2 may be sufficient for effective topical ALA- PDT of disseminated, mild to moderate AK on the face and scalp. | Radakovic-Fijan S. Blecha-ThalhammerU. Kittler H. A. Tanew 冯义国 | 2006 | 世界核心医学期刊文摘(皮肤病学分册)2006，0，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员